WHILL model F and C2 with Stealth Accessories
WHILL Power Chairs Announces Partnership With Stealth Products
24 oct. 2022 12h00 HE | WHILL Inc.
SAN FRANCISCO, Oct. 24, 2022 (GLOBE NEWSWIRE) -- WHILL, Inc., award-winning provider of electric mobility chairs, and Stealth Products LLC, announced a new partnership whereby seating and...
Vial Filling at BSM
Berkshire Sterile client receives FDA approval on product indicated to reduce risk of hearing loss for childhood cancer patients
29 sept. 2022 11h00 HE | Berkshire Sterile Manufacturing
Lee, MA, Sept. 29, 2022 (GLOBE NEWSWIRE) -- On September 21st, 2022, Berkshire Sterile Manufacturing’s (BSM) client, Fennec Pharmaceuticals Inc., received FDA approval of their drug product, PEDMARK...
Arcutis logo.png
FDA Approves Arcutis’ ZORYVE™ (Roflumilast) Cream 0.3% For the Treatment of Plaque Psoriasis in Individuals Age 12 and Older
29 juil. 2022 16h05 HE | Arcutis Biotherapeutics, Inc.
First and only topical PDE4 inhibitor approved for the treatment of plaque psoriasis, including intertriginous psoriasis Approved for once-daily treatment in mild, moderate, and severe plaque...
Neovasc_Logo-web-header.jpg
Neovasc Announces FDA Approval of Planned COSIRA II Sub-studies and Single Arm Registry to Allow Inclusion of Additional Specified Patient Populations
26 juil. 2022 09h05 HE | Neovasc, Inc.
VANCOUVER and MINNEAPOLIS, July 26, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today announced the United States Food and Drug...
Aussie Company Care A2+ Gains FDA Approval to Address US Infant Formula Shortages
09 juil. 2022 09h00 HE | Care A2+
SYDNEY, July 09, 2022 (GLOBE NEWSWIRE) -- Care A2+, an Australian health and wellness company, today announced it has been approved by the United States Food & Drug Administration (FDA) to...
logo_no_tag_2c.jpg
FDA Approves Sientra’s Low Plus Profile Projection Breast Implant
06 juil. 2022 09h00 HE | Sientra, Inc.
SANTA BARBARA, Calif., July 06, 2022 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”) announced today that the U.S. Food and Drug Administration (FDA) approved the Low...
Spero Class Action Complaint Filed: Johnson Fistel, Globally Recognized Law Firm, Encourages Shareholders to Submit Their Losses
26 mai 2022 17h21 HE | Johnson Fistel, LLP
SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of Spero Therapeutics, Inc....
MJNA_Logo.png
Medical Marijuana, Inc. Subsidiary Kannaway® Announces Positive Preliminary Results of Validcare CBD Safety Study
18 mai 2022 09h00 HE | Medical Marijuana, Inc.
SAN DIEGO, CA, May 18, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that...
Phathom_Pharm_Logo_RGB.jpg
Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA™ TRIPLE PAK™ (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA™ DUAL PAK™ (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults
03 mai 2022 17h40 HE | Phathom Pharmaceuticals
VOQUEZNA TRIPLE and DUAL PAKs each contain vonoprazan, a novel, first-in-class potassium-competitive acid blocker (PCAB), and have demonstrated superior eradication rates vs. lansoprazole-based triple...
Logo.png
Biofrontera Inc. Announces FDA Approval of Biofrontera Pharma GmbH as a Contract Laboratory for Ameluz®
13 avr. 2022 10h10 HE | Biofrontera Inc.
Significantly Improves Manufacturing Efficiency, Quality Control and Supply Reliability WOBURN, Mass., April 13, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical...